Advertisement

A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis

  • Zhu Jing
  • Zhou Rui
  • Zhang binglanEmail author
Original Article – Clinical Oncology
  • 101 Downloads

Abstract

Background

The optimal treatment in the third-line and later-line setting for metastatic colorectal cancer (mCRC) has not been established. As reported, regorafenib and fruquintinib have shown to be superior to placebo in mCRC. However, no direct clinical comparison of regorafenib and fruquintinib has been conducted; we performed a systematic review and network meta-analysis to compare the efficacy and safety of regorafenib and fruquintinib.

Methods

PubMed, Embase, and the Cochrane Library were systematically searched and randomized-controlled trials (RCTs) assessing the effect and safety of regorafenib or fruquintinib versus placebo for patients with mCRC were included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. After that, we performed pairwise direct meta-analyses (regorafenib vs. placebo and fruquintinib vs. placebo) and indirect comparison (regorafenib vs. fruquintinib) using network meta-analyses methods.

Results

Three RCTs involving 1380 patients were included in the meta-analysis. In the direct meta-analysis, regorafenib and fruquintinib both showed survival benefits when compared with placebo. For the indirect comparison, fruquintinib shows no significant difference in OS compared to regorafenib (HR 0.97; 95% CI 0.64–1.46). Regarding PFS, there was a tendency that fruquintinib was superior to regorafenib (HR 0.65; 95% CI 0.39–1.08); however, there was no statistic difference. For the safety analysis, in indirect comparison, fruquintinib showed significant difference in all-grade toxicity compared to regorafenib (OR 0.73; 95% CI 0.65–0.82), especially in subgroup of proteinuria (OR 0.31; 95% CI 0.11–0.86). For the grade 3–5 toxicity, fruquintinib showed no significant difference when compared with regorafenib (OR 0.92; 95% CI 0.64–1.32).

Conclusion

Based on efficacy and safety, there was a tendency that fruquintinib was superior to regorafenib, as a whole, regorafenib and fruquintinib demonstrated similar clinical benefit for patients with refractory mCRC. It seems that fruquintinib has less toxic in all-grade toxicity when compared with regorafenib.

Keywords

Comparative effectiveness Network meta-analysis Metastatic colorectal cancer Regorafenib Fruquintinib 

Notes

Funding

This study was supported by the National Natural Science Foundation of China (Grant numbers 81803569).

Compliance with ethical standards

Conflict of interest

All the authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. Abrahao ABK, Ko YJ, Berry S, Chan KKW (2018) A comparison of regorafenib and TAS-102 for metastatic colorectal cancer: a systematic review and network meta-analysis. Clin Colorectal Cancer 17:113–120CrossRefGoogle Scholar
  2. Bekaii-Saab TS, Ou FS, Ciombor KK et al (2016) Regorafenib dose optimization study (ReDOS): a phase II randomized study of lower starting dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer (mCRC). J Clin Oncol.  https://doi.org/10.1200/JCO.2016.34.15_suppl.TPS3630 Google Scholar
  3. Bekaii-Saab T, Kim R, Kim TW et al (2019) Third- or later-line therapy for metastatic colorectal cancer: reviewing best practice. Clin Colorectal Cancer 18:e117–e129CrossRefGoogle Scholar
  4. Benson AB 3rd, Venook AP, Bekaii-Saab T et al (2015) Rectal cancer, version 2.2015. J Natl Compr Cancer Netw 13:719–728 (Quiz 728) CrossRefGoogle Scholar
  5. Benson AB 3rd, Venook AP, Cederquist L et al (2017) Colon Cancer, Version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15:370–398CrossRefGoogle Scholar
  6. Bozzarelli S, Rimassa L, Giordano L, et al (2016) Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND). Annals of oncology. Conference: 41st european society for medical oncology congress, ESMO 2016. Denmark. Conference start: 20161007. Conference end: 20161011Google Scholar
  7. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 68:394–424CrossRefGoogle Scholar
  8. Byrne M, Saif MW (2019) Selecting treatment options in refractory metastatic colorectal cancer. Onco Target Ther 12:2271–2278CrossRefGoogle Scholar
  9. Caldwell DM, Ades AE, Higgins JP (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331:897–900CrossRefGoogle Scholar
  10. Cao J, Zhang J, Peng W et al (2016) A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemother Pharmacol 78:259–269CrossRefGoogle Scholar
  11. Ciardiello F, Salvatore L, Cascinu S et al (2015) Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study. Ann Oncol 26:vi37CrossRefGoogle Scholar
  12. Ferlay J, Colombet M, Soerjomataram I et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941–1953Google Scholar
  13. Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (London, England) 381:303–312CrossRefGoogle Scholar
  14. Gu Y, Wang J, Li K et al (2014) Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. Cancer Chemother Pharmacol 74:95–115CrossRefGoogle Scholar
  15. Higgins JP, Altman DG, Gotzsche PC et al (2011) The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928CrossRefGoogle Scholar
  16. Hofheinz RD, Giardello F, Seitz JF et al (2016) CONSIGN-an open-label phase-3B-study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy. Oncol Res Treat 39:10Google Scholar
  17. Jprn U (2013) Randomized phase II Study of regorafenib followed by cetuximab versus Reverse Sequence for wild-type KRAS metastatic colorectal cancer previously treated with Fluoropyrimidine, Oxaliplatin, and Irinotecan (REVERECE). http://www.who.int/trialsearch/trial2.aspx? Trialid = jprn-umin000011294. Accessed Apr 2019
  18. Knobloch K, Yoon U, Vogt PM (2011) Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg 39:91–92CrossRefGoogle Scholar
  19. Kopeckova K, Buchler T, Bortlicek Z et al (2017) Regorafenib in the real-life clinical practice: data from the czech registry. Target Oncol 12:89–95CrossRefGoogle Scholar
  20. Lenz HJ, Stintzing S, Loupakis F (2015) TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev 41:777–783CrossRefGoogle Scholar
  21. Li J, Qin S, Xu R et al (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16:619–629CrossRefGoogle Scholar
  22. Li J, Qin S, Xu RH et al (2018) Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA 319:2486–2496CrossRefGoogle Scholar
  23. Marcus L, Lemery SJ, Khasar S et al (2017) FDA approval summary: TAS-102. Clin Cancer Res 23:2924–2927CrossRefGoogle Scholar
  24. Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909–1919CrossRefGoogle Scholar
  25. Neupane B, Richer D, Bonner AJ, Kibret T, Beyene J (2014) Network meta-analysis using R: a review of currently available automated packages. PLoS One 9:e115065CrossRefGoogle Scholar
  26. Rucker G, Schwarzer G (2016) Automated drawing of network plots in network meta-analysis. Res Synth Method 7:94–107CrossRefGoogle Scholar
  27. Salanti G, Higgins JP, Ades AE, Ioannidis JP (2008) Evaluation of networks of randomized trials. Stat Method Med Res 17:279–301CrossRefGoogle Scholar
  28. Sun Q, Zhou J, Zhang Z et al (2014) Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther 15:1635–1645CrossRefGoogle Scholar
  29. Tampellini M, Di Maio M, Baratelli C et al (2017) Treatment of patients with metastatic colorectal cancer in a real-world scenario: probability of receiving second and further lines of therapy and description of clinical benefit. Clin Colorectal Cancer 16:372–376CrossRefGoogle Scholar
  30. US Food and Drug Administration (2012) FDA approves regorafenib (Stivarga) for metastatic colorectal cancer. Oncol (Williston Park) 26:896Google Scholar
  31. Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422CrossRefGoogle Scholar
  32. Vogel A, Hofheinz RD, Kubicka S, Arnold D (2017) Treatment decisions in metastatic colorectal cancer—beyond first and second line combination therapies. Cancer Treat Rev 59:54–60CrossRefGoogle Scholar
  33. Xu RH, Li J, Bai Y et al (2017) Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol 10:22CrossRefGoogle Scholar
  34. Yoshino T, Mizunuma N, Yamazaki K et al (2012) TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13:993–1001CrossRefGoogle Scholar
  35. Yoshino T, Arnold D, Taniguchi H et al (2018) Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29:44–70CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of OncologyThe First Affiliated Hospital of Chongqing Medical UniversityChongqingChina
  2. 2.Department of GastroenterologyThe First Affiliated Hospital of Chongqing Medical UniversityChongqingChina

Personalised recommendations